Aptevo Therapeutics Inc (OQ:APVO)

May 08, 2024 08:05 am ET
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease and transitioning to higher dose with potential for greater clinical benefit, experienced no new adverse events since the transition to the higher dose level
Apr 15, 2024 04:05 pm ET
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
SEATTLE, WA / ACCESSWIRE / April 15, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "Common Warrants") at a purchase price of $1.35 per share
Apr 11, 2024 08:00 am ET
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
SEATTLE, WA / ACCESSWIRE / April 11, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "Common Warrants") at a purchase price of $1.35 per share and associated Common
Apr 10, 2024 09:00 am ET
Aptevo Therapeutics Provides Pipeline Update
SEATTLE, WA / ACCESSWIRE / April 10, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced advancements in both clinical programs and one preclinical program.
Mar 18, 2024 06:00 am ET
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company is participating in The Springtime Event, a Bio-Europe conference occurring March 18-20, 2024 in Barcelona, Spain.
Mar 07, 2024 08:55 am ET
Mar 05, 2024 08:05 am ET
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24
Mar 04, 2024 09:00 am ET
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
SEATTLE, WA / ACCESSWIRE / March 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-44 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on March 5, 2024 at 5:01 p.m. Eastern Time (the "Effective Time"), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted, at market open on March 6, 2024. In con
Dec 28, 2023 08:31 am ET
Thinking about buying stock in Fusion Pharmaceuticals, Aptevo Therapeutics, Blink Charging, Ampio Pharmaceuticals, or Bitcoin Depot?
NEW YORK, Dec. 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FUSN, APVO, BLNK, AMPE, and BTM.
Nov 14, 2023 08:05 am ET
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to Progress
Nov 01, 2023 07:45 am ET
Aptevo to Present at Bio-Europe Conference
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company will present at the upcoming Bio-Europe conference occurring November 6-8, 2023 in Munich, Germany.
Aug 10, 2023 08:05 am ET
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AML
Aug 04, 2023 06:40 pm ET
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced the closing of its previously announced public offering of 2,221,550 shares of common stock at a purchase price of $0.62 per share, Pre-Funded Warrants to purchase up to an aggregate of 5,842,967 shares of common stock at a purchase price of $0.619 per Pre-Funded Warrant, Series A Warrants to purchase up to an aggregate of 8,064,517 sha
Aug 01, 2023 10:15 pm ET
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
SEATTLE, WA / ACCESSWIRE / August 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced that the Company has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of 8,064,517 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.62 per share. The Company further agreed to issue to the investors Series A Warrants to purchase up
Jul 18, 2023 08:05 am ET
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of Care
May 11, 2023 08:05 am ET
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet Debt
Mar 30, 2023 07:45 am ET
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid Tumors
Mar 30, 2023 07:30 am ET
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
Completes Sale of IXINITY Deferred Payments and Portion of Milestones from Medexus to XOMA Corporation
Feb 13, 2023 08:05 am ET
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4
Jan 09, 2023 08:05 am ET
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
New PD-L1 x CD40 Candidate Built on Proprietary ADAPTIR™ Platform, Enters Pre-Clinical Pipeline
Dec 12, 2022 07:35 am ET
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve
Dec 12, 2022 07:34 am ET
Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals?
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTGM, HARP, ACER, APVO, and TNXP.
Nov 10, 2022 08:05 am ET
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Company to Present New APVO436 Expansion Phase Trial Data at Upcoming American Society of Hematology Annual Meeting and Exposition
Nov 09, 2022 08:05 am ET
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB Antibody
Nov 03, 2022 09:06 am ET
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
Company to Present New Data from On-Going Phase 1b Trial Evaluating Lead Candidate APVO436 for the Treatment of Acute Myeloid Leukemia
Sep 19, 2022 08:45 am ET
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types
Aug 11, 2022 08:05 am ET
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
SEATTLE, WA / ACCESSWIRE / August 11, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended June 30, 2022.
Jun 09, 2022 08:05 am ET
May 12, 2022 08:05 am ET
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended March 31, 2022.
Apr 12, 2022 08:05 am ET
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease
Mar 29, 2022 09:31 am ET
Thinking about buying stock in Clever Leaves, Grid Dynamics, Aptevo Therapeutics, Ginkgo Bioworks, or Academy Sports and Outdoors?
NEW YORK , March 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVR, GDYN, APVO, DNA, and ASO.
Mar 29, 2022 08:05 am ET
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status
Mar 24, 2022 08:05 am ET
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
SEATTLE, WA / ACCESSWIRE / March 24, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results for the year ended December 31, 2021 and provided 2021 business highlights.
Feb 09, 2022 08:05 am ET
Jan 21, 2022 08:05 am ET
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
Vice Chairman, John E. Niederhuber, M.D., to Assume Chairmanship, Effective April 1, 2022
Dec 15, 2021 08:05 am ET
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications, on the mechanism of action of 4-1BB targeting bispecific antibodies. Nature Communications is an open access, multidisciplinary journal dedicated to publishing high-quality research in all areas of the biological, health, physical, chemi
Dec 13, 2021 08:31 am ET
Thinking about buying stock in Turquoise Hill Resources, Clear Channel Outdoor, Aptevo Therapeutics, Arbutus Biopharma, or American Virtual Cloud Technologies?
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRQ, CCO, APVO, ABUS, and AVCT.
Nov 24, 2021 09:55 am ET
Thinking about buying stock in Palatin Technologies, ContextLogic, Nordstrom, Aptevo Therapeutics, or BioNano Genomics?
NEW YORK, Nov. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTN, WISH, JWN, APVO, and BNGO.
Nov 23, 2021 08:45 am ET
Thinking about buying stock in Aptevo Therapeutics, Navitas Semiconductor, Berkshire Grey, Aadi Bioscience, or Emergent Biosolutions?
NEW YORK, Nov. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APVO, NVTS, BGRY, AADI, and EBS.
Nov 23, 2021 08:05 am ET
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
SEATTLE, WA / ACCESSWIRE / November 23, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced a clinical update for the Company's Phase 1b Expansion trial evaluating APVO436 in the treatment of acute myeloid leukemia (AML). Preliminary data observed to date includes one complete remission.
Nov 15, 2021 08:05 am ET
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company will present two abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually and in-person in Atlanta, Ga. December 11-14, 2021.
Nov 12, 2021 08:05 am ET
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results and business highlights for the quarter ended September 30, 2021.
Nov 11, 2021 08:30 am ET
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific
Nov 02, 2021 09:00 am ET
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the...
Oct 27, 2021 08:05 am ET
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, will participate at the 2nd Virtual Congress on Controversies in Leukemias (EuroLeuk), an international leukemia symposium which is being held October 28-29, 2021, with a Poster Presentation. The poster abstract was selected as one of the best abstracts a
Oct 26, 2021 08:05 am ET
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the peer-reviewed journal Cancers published results of the Company's research on mitigation of the risk of cytokine release syndrome (CRS) as well as its effective management in patients with acute myeloid leukemia (AML) or myelodysplasti
Sep 28, 2021 08:05 am ET
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS)
Aug 17, 2021 08:05 am ET
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
SEATTLE, WA / ACCESSWIRE / August 17, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the publication of a peer-reviewed research article in the prestigious oncology journal Cancers. The research article reports the results of a multi-institutional Phase 1 clinical study of Apte
Aug 12, 2021 08:05 am ET
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results and business highlights for the quarter ended June 30, 2021.
Jul 16, 2021 08:05 am ET
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that Dr. Jane Gross, Senior Vice President of Research and Development and Chief Scientific Officer of Aptevo, will give a presentation and participate in a live interactive panel discussion at the Cambridge Health Institute PEGS Virtual Conference being hosted from Monday, July
Jun 30, 2021 08:05 am ET
Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit
SEATTLE, WA / ACCESSWIRE / June 30, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that three members of the Company's scientific team will present at the upcoming Virtual Cell Engager Summit being hosted from Tuesday, June 29, 2021 through Thursday, July 1, 2021. The conference is focused on strategies to "accelerate approval of cell engager therapies.
Jun 29, 2021 08:05 am ET
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
About the Russell IndexesRussell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FT
May 27, 2021 09:00 am ET
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial
May 26, 2021 09:00 am ET
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
SEATTLE, WA / ACCESSWIRE / May 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced positive results from the Company's Phase 1 dose escalation trial evaluating lead ADAPTIR candidate, APVO436, for the treatment of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS). APVO436 was generally well tolerated and demonstrated a favorable side effect profile, inclu
May 11, 2021 09:00 am ET
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing
Apr 09, 2021 09:00 am ET
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today announced that it will present two new posters at the American Association for Cancer Research Virtual Annual Meeting, to be held in two virtual sessions - Saturday, April 10th to Thursday, April 15th, 2021 and Monday, May 17th to Friday, May 21st, 2021.
Mar 31, 2021 08:00 am ET
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing
Feb 09, 2021 07:30 pm ET
Aptevo Confirms Receipt of Nominations and Proposal Notice
Stockholders Are Not Required to Take Any Action at this Time
Jan 11, 2021 08:00 am ET
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.
Dec 02, 2020 08:00 am ET
Nov 19, 2020 04:15 pm ET
Aptevo Confirms Receipt of Unsolicited Indication of Interest
SEATTLE, WA / ACCESSWIRE / November 19, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received an unsolicited non-binding indication of interest from Tang Capital Partners, LP expressing its interest in acquiring all of the outstanding shares of Aptevo that it does not already own for $50.00 per share in cash.
Nov 19, 2020 07:30 am ET
Thinking about buying stock in Aptevo Therapeutics, Electrameccanica Vehicles, AstraZeneca, Corcept Therapeutics, or 22nd Century Group?
NEW YORK, Nov. 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APVO, SOLO, AZN, CORT, and XXII.
Nov 16, 2020 08:00 am ET
Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development
SEATTLE, WA / ACCESSWIRE / November 16, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience ("Alligator") (Nasdaq Stockholm:ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today provided an update on ALG.APV-527, a novel immunotherapeutic bispecific candidate intended for the treatment of multiple solid tumors express
Nov 11, 2020 08:31 am ET
Thinking about buying stock in Surface Oncology, Northern Oil & Gas, Co-Diagnostics, Howmet Aerospace, or Aptevo Therapeutics?
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SURF, NOG, CODX, HWM, and APVO.
Nov 10, 2020 04:40 pm ET
Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update
$1.5 million of RUXIENCE® Royalties Earned in the Third Quarter
Nov 09, 2020 09:00 am ET
Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting
SEATTLE, WA / ACCESSWIRE / November 9, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it will present two new posters at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting, to be held from Monday, November 9, 2020 to Saturday, November 14, 2020.
Nov 09, 2020 07:30 am ET
Thinking about buying stock in American Airlines, Carnival Corp, Pfizer, Aptevo Therapeutics, or Aurora Cannabis?
NEW YORK, Nov. 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, CCL, PFE, APVO, and ACB.
Nov 09, 2020 06:00 am ET
Nov 08, 2020 11:15 pm ET
Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan
SEATTLE, WA / ACCESSWIRE / November 8, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is November 23, 2020. The rights plan expires, without any further action be
Nov 03, 2020 09:40 am ET
Thinking about buying stock in Sundial Growers, Aptevo Therapeutics, Aphria Inc, Medifast, or Freeport-McMoRan?
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, APVO, APHA, MED, and FCX.
Nov 03, 2020 09:00 am ET
Sep 01, 2020 09:00 am ET
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
Trial Advancing on Schedule and Second Patient Dosed in Cohort 7
Aug 14, 2020 09:00 am ET
Aptevo Therapeutics Reports Second Quarter 2020 Financial Results
SEATTLE, WA / ACCESSWIRE / August 14, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today provided a business review and reported its financial results for the second quarter ended June 30, 2020.
Aug 06, 2020 09:00 am ET
Jul 21, 2020 09:00 am ET
Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones
SEATTLE, WA / ACCESSWIRE / July 21, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, has engaged Piper Sandler to sell its RUXIENCE® and IXINITY® royalty streams and milestone payments.
Jun 29, 2020 09:00 am ET
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale
SEATTLE, WA / ACCESSWIRE / June 29, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, announced today that it has collected in full the $750,000 placed into an escrow account for working capital adjustments. This collection relates to the Company's sale of its Hemophilia B therapy, IXINITY®, to Medexus Pharmaceuticals.
Jun 25, 2020 10:35 am ET
Thinking about buying stock in Ekso Bionics, Apple Inc, GNC Holdings, Microsoft Corp, or Aptevo Therapeutics?
NEW YORK, June 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EKSO, AAPL, GNC, MSFT, and APVO.
Jun 25, 2020 09:00 am ET
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar
SEATTLE, WA / ACCESSWIRE / June 25, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it will receive a royalty from Pfizer related to sales of a rituximab biosimilar product, RUXIENCE® (Rituximab-pvvr), which was approved by the U.S. Food and Drug Administration in July 2019 and launched by Pfizer in the United States and Japan in early 2020.
Jun 10, 2020 09:00 am ET
May 13, 2020 09:00 am ET
Aptevo Therapeutics Reports First Quarter 2020 Financial Results
SEATTLE, WA / ACCESSWIRE / May 13, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today provided a business review and reported its financial results for the first quarter ended March 31, 2020.
Apr 14, 2020 09:00 am ET
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements
SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) on April 13, 2020 informing Aptevo that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Aptevo is now in compliance with all applicable lis
Mar 25, 2020 09:00 am ET
Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update
Advances Dose-Escalation Phase 1/1b Study of APVO436 for Treatment ofAcute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome
Mar 16, 2020 09:00 am ET
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial
Trial Advancing on Schedule with Dosing in Cohort 6 Set to Begin Shortly;Dose Levels Now Entering Potential Therapeutic Range No Evidence of Dose-Limiting Toxicities Observed in Cohort 5No Evidence of Drug-Induced Anti-Drug Antibodies Observed to Date
Feb 28, 2020 09:05 am ET
Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million
Transforms Aptevo into a ‘Pure Play' Biotechnology Company Focused on the Development of Proprietary ADAPTIR™ Bispecific Antibody Therapeutics
Feb 28, 2020 08:59 am ET
Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced that the Company, through its US-based subsidiary, acquired Aptevo BioTherapeutics LLC, a Delaware limited liability company owning the worldwide...
Jan 30, 2020 09:00 am ET
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion
Clinical Data Intended to be Used to Support Pediatric Label Expansion for IXINITY
Jan 13, 2020 08:00 am ET
Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial
APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead Sciences, Takeda Oncology, Agios Pharmaceuticals, Astellas Pharma and Boehringer Ingelheim as an Industry Participant in the Study Beat AML Master Clinical Trial Represents a Groundbreaking, First-of-its-Kind Collaboration Between Academia, Leading Clinical Research Centers, Biopharmaceutical Companies and Government Spearheaded by The Leukem
Dec 06, 2019 09:00 am ET
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to...
Nov 08, 2019 09:00 am ET
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based...
Nov 07, 2019 09:00 am ET
Aptevo Therapeutics Reports Third Quarter 2019 Financial Results
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the third quarter ended September 30, 2019....
Oct 03, 2019 04:02 pm ET
Aptevo Therapeutics Provides Corporate and Pipeline Update
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a corporate and pipeline update. IXINITY Results – Record Net Revenue and New Patient Conversions...
Sep 19, 2019 09:00 am ET
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today introduced a new immuno-oncology candidate, APVO603, built on Aptevo’s proprietary ADAPTIR™...
Aug 09, 2019 09:00 am ET
Aptevo Therapeutics Reports Second Quarter 2019 Financial Results
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today provided a business review and reported its financial results for the second quarter ended June 30,...
Aug 07, 2019 09:02 am ET
Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the receipt of a $4.3 million milestone payment from Saol International Limited (Saol). This...
Jul 25, 2019 04:32 pm ET
Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has completed dosing in a single ascending dose (SAD) Phase 1 study of APVO210, a...
Jun 25, 2019 09:00 am ET
Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it has launched a new, larger 3000 IU (international unit) vial size for IXINITY®...
May 09, 2019 09:00 am ET
Aptevo Therapeutics Reports First Quarter 2019 Financial Results
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today provided a business review and reported its financial results for the first quarter ended March 31,...
Apr 18, 2019 07:30 am ET
Research Report Identifies Fastenal, Ideal Power, Fuel Tech, CTI BioPharma, Aptevo Therapeutics, and Caseys General Stores with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fastenal Company (NASDAQ:FAST), Ideal Power Inc. (NASDAQ:IPWR), Fuel Tech,...
Apr 15, 2019 09:00 am ET
Aptevo Therapeutics Reports IXINITY® and Pipeline Progress
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced continued progress in the Company’s commercial and clinical development programs,...
Apr 02, 2019 09:02 am ET
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that new preclinical data for two ADAPTIR bispecific candidates, APVO436, a bispecific...
Mar 25, 2019 09:02 am ET
Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR™ bispecific antibody candidates will be...
Mar 20, 2019 09:02 am ET
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has commenced dosing in a Phase 1 clinical trial of APVO210, a novel bispecific...
Mar 18, 2019 09:00 am ET
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today reported its financial results for the year ended December 31, 2018 and provided an update on its...
Mar 07, 2019 09:13 am ET
Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering price of $1.00 per share of common...
Mar 06, 2019 04:37 pm ET
Aptevo Announces Proposed Public Offering of Common Stock and Warrants
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its...
Jan 07, 2019 08:30 am ET
Aptevo Therapeutics Highlights Key 2019 Priorities
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today outlined key priorities for the Company in 2019 centered around anticipated progress in its ADAPTIR bispecific...
Jan 03, 2019 09:02 am ET
Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has collected $3.3 million in escrow funds from Saol Therapeutics related to a purchase...
Dec 21, 2018 09:00 am ET
Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has entered into a common stock purchase agreement and registration rights agreement with...
Dec 13, 2018 09:02 am ET
Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the first patient has been dosed in a Phase 1/1b clinical trial of APVO436, a novel anti-CD123...
Dec 11, 2018 07:20 am ET
United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercer International Inc. (NASDAQ:MERC), United Parcel Service, Inc....
Nov 20, 2018 09:00 am ET
Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday,...
Nov 14, 2018 04:02 pm ET
Aptevo Therapeutics Reports Third Quarter 2018 Financial Results
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the third quarter ended September 30, 2018....
Nov 09, 2018 12:00 am ET
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, and Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel...
Oct 24, 2018 09:00 am ET
Aptevo Therapeutics Announces Expanded Growth Initiatives for IXINITY
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided an update on its growth strategy for IXINITY® [Coagulation Factor IX (Recombinant)] in the United...
Oct 10, 2018 08:40 am ET
Market Trends Toward New Normal in Aptevo Therapeutics, Bottomline Technologies, Allete, Air Lease, The Goodyear Tire & Rubber, and EastGroup Properties — Emerging Consolidated Expectations, Analyst R
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Aptevo Therapeutics Inc. (NASDAQ:APVO), Bottomline Technologies, Inc....
Sep 25, 2018 11:29 am ET
Aptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday,...
Aug 09, 2018 09:00 am ET
Aptevo Therapeutics Reports Second Quarter 2018 Financial Results
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the second quarter ended June 30, 2018. “We...
Aug 07, 2018 09:00 am ET
Aptevo Therapeutics Revises Term Loan Agreement With MidCap Financial; Reduces Cash Requirements by $18 Million
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that it has executed a new agreement amending the terms of its original $20 million term loan...
Aug 06, 2018 08:10 am ET
Report: Developing Opportunities within athenahealth, W.R. Berkley, Air Products and Chemicals, DICK'S Sporting Goods, Aptevo Therapeutics, and Columbia Property Trust — Future Expectations, Projectio
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of athenahealth, Inc. (NASDAQ:ATHN), W.R. Berkley Corporation (NYSE:WRB), Air...
May 29, 2018 09:00 am ET
Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the publication of preclinical data in Frontiers in Immunology highlighting the activity of APVO210 as...
May 10, 2018 09:00 am ET
Aptevo Therapeutics Reports First Quarter 2018 Financial Results
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the first quarter ended March 31, 2018. “I’m...
May 08, 2018 09:02 am ET
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, and Alligator Bioscience (Nasdaq Stockholm:ATORX), a biotechnology company developing antibody-based...
May 01, 2018 09:00 am ET
Aptevo Therapeutics Announces IND Submission for APVO436
New Preclinical Data Presented at AACR Support Best-in-Class Features of APVO436 Highlighting Reduced Cytokine Release and Antibody-Like Half-Life and Manufacturing
Apr 30, 2018 07:50 am ET
Report: Developing Opportunities within Natus Medical, Aptevo Therapeutics, Revlon, Silgan, Resources Connection, and TrustCo Bank Corp NY — Future Expectations, Projections Moving into 2018
NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natus Medical Incorporated (NASDAQ:BABY), Aptevo Therapeutics...
Apr 16, 2018 09:02 am ET
Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release
New Preclinical Data Presented at the 2018 American Association for Cancer Research Annual Meeting Show Potent T-Cell Directed Tumor Killing with Reduced Cytokine Production Compared to a Competitor Bispecific Construct
Mar 19, 2018 08:20 am ET
Research Report Identifies Ambarella, Merit Medical, NETGEAR, Independent Bank, Cutera, and Aptevo Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ambarella, Inc. (NASDAQ:AMBA), Merit Medical Systems,...
Mar 13, 2018 09:02 am ET
Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update
Completes Sale of Hyperimmune Commercial Business for up to $74.5 Million
Mar 12, 2018 09:02 am ET
Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY
Data Presented at the Thrombosis and Hemostasis 2018 Summit of North America
Feb 27, 2018 09:02 am ET
Aptevo Therapeutics to Present at the 30th Annual ROTH Conference
SEATTLE, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30th Annual ROTH Conference on Tuesday March...
Jan 17, 2018 08:10 am ET
Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet — New Horizons, Emerging Trends, and Upcoming Deve
NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Alarm.com Holdings,...
Jan 08, 2018 09:00 am ET
Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma
SEATTLE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has commenced patient dosing in a Phase 2 clinical evaluation of otlertuzumab...
Dec 11, 2017 09:02 am ET
Aptevo Therapeutics’ Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples
New APVO436 Preclinical Data Show Robust T-Cell Engagement and Cytotoxicity in AML Patient Specimens
Nov 28, 2017 07:02 am ET
Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma
Anticipates 2 IND Filings in 2018 for Novel Bispecific Antibody Candidates
Nov 14, 2017 04:02 pm ET
Aptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference
SEATTLE, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 29th Annual Piper Jaffray Healthcare Conference on...
Nov 09, 2017 04:30 pm ET
Aptevo Therapeutics Reports Third Quarter 2017 Financial Results
Strengthened Cash Position to Support Ongoing R&D and Commercial Activities; Reported $107 Million in Cash at the End of the Third Quarter ...
Nov 09, 2017 04:30 pm ET
Aptevo Therapeutics Reports Third Quarter 2017 Financial Results
Strengthened Cash Position to Support Ongoing R&D and Commercial Activities; Reported $107 Million in Cash at the End of the Third Quarter
Sep 28, 2017 04:45 pm ET
Aptevo Therapeutics Extends Cash Runway $20 Million; Retains Term Loan Agreement With MidCap Financial
SEATTLE, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that it has amended the terms of a credit agreement initially executed with MidCap Financial Trust in August 2016. The first tranche of this term loan, in the amount of $20 million, was funded in August 2016.  The amendment allows Aptevo to retain this $20 million funding tranche, for which repayment was anticipated coincident with the sale transaction of Aptevo’s hyperimmune commercial assets.  As...
Sep 28, 2017 04:35 pm ET
Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million
Sharpens Focus on Innovative ADAPTIR® Bispecific Antibody Platform and IXINITY® Commercial Asset...
Jul 20, 2017 05:19 pm ET
Aptevo Therapeutics and Alligator Bioscience Announce Plans to Co-Develop Novel Bispecific Antibody for Tumor-Directed Immunotherapy
Strategic Partnership Will Advance Development of a Novel BispecificImmuno-Oncology Antibody Targeting Compelling Biological PathwayImplicated in Multiple Solid Tumor Indications...
Mar 06, 2017 08:30 am ET
Aptevo Therapeutics to Present at the 29th Annual ROTH Conference
SEATTLE, March 06, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 29th Annual ROTH Conference on Wednesday, March 15, 2017 at 10:30 AM PT at the Ritz Carlton, Laguna Niguel, California....
Dec 15, 2016 01:54 pm ET
Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MOR209/ES414
SEATTLE, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO) a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has amended the terms of its collaboration agreement with MorphoSys AG, originally executed in August 2014, for the joint worldwide development and commercialization of MOR209/ES414, a novel bispecific immuno-oncology therapeutic currently being evaluated in a Phase 1 clinical study for the treatment of metastatic castration-resistant prostate cancer (mCRPC.)...
Sep 15, 2016 10:30 am ET
Aptevo Therapeutics Augments Leadership Team
Appoints Former GlaxoSmithKline Executive Randy Maddux Senior Vice President, Operations...
Aug 01, 2016 07:00 am ET
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics
GAITHERSBURG, Md., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through the distribution of all of the shares of Aptevo common stock to the holders of Emergent BioSolutions common stock. As a result of the spin-off, Aptevo is now an independent public company and listed on the Nasdaq Global Select Market under the ticker symbol “APVO.”...
Jul 20, 2016 07:00 am ET
Emergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common Stock
GAITHERSBURG, Md., July 20, 2016 (GLOBE NEWSWIRE) -- In connection with the spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through a dividend distribution by Emergent BioSolutions Inc. (NYSE:EBS) of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, Emergent announced that Aptevo common stock will commence trading today, July 20, 2016, on a “when issued” basis under the symbol “APVOV” on the Nasdaq Global Select Market. ...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.